{Reference Type}: Journal Article
{Title}: Analysis of orphan designation status for FDA approved drugs, and case studies in oncology, neuroscience and metabolic diseases.
{Author}: Brown DG;Wobst HJ;
{Journal}: Bioorg Med Chem
{Volume}: 80
{Issue}: 0
{Year}: 02 2023 15
{Factor}: 3.461
{DOI}: 10.1016/j.bmc.2023.117170
{Abstract}: Many new drugs have been approved over the past decade for rare or orphan diseases. The passage of the Orphan Drug Act (ODA) in 1983 has provided key economic and regulatory incentives to provide medicines for patients who are suffering from rare diseases that may not be commercially attractive for research and development. We have analyzed 497 novel drugs approved from 2010 - June 13, 2022, of which 220 were given orphan designation status. We discuss trends over this time period, potential risks for long development times, and provide example case studies of successful development and launch of novel drugs for rare diseases.